Phase II trial on SBRT for unresectable liver metastases: long-term outcome and prognostic factors of survival after 5 years of follow-up.

Marta ScorsettiTiziana ComitoElena ClericiCiro FranzeseAngelo TozziCristina IftodeLucia Di BrinaPierina NavarriaPietro MancosuGiacomo ReggioriAntonella FogliataStefano TomatisGuido TorzilliLuca Cozzi

Published in: Radiation oncology (London, England) (2018)

Long-term results of this Phase II study suggest the efficacy and safety of SBRT for un-resectable liver metastases after 5-year of follow up. Selection of cases with positive prognostic factors may improve long-term survival of these oligo-metastastic patients and may confirm the role of SBRT as an effective alternative local therapy for liver metastases.

Keyphrases

liver metastases
prognostic factors
radiation therapy
phase ii study
open label
locally advanced
end stage renal disease
chronic kidney disease
clinical trial
ejection fraction
peritoneal dialysis
double blind